Arcellx, Inc. (ACLX)
| Market Cap | 6.75B +107.8% |
| Revenue (ttm) | 22.29M -79.4% |
| Net Income | -228.93M |
| EPS | -4.07 |
| Shares Out | 58.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,195,164 |
| Open | 115.04 |
| Previous Close | 115.03 |
| Day's Range | 115.03 - 115.13 |
| 52-Week Range | 47.86 - 115.13 |
| Beta | 0.25 |
| Analysts | Hold |
| Price Target | 115.85 (+0.64%) |
| Earnings Date | May 6, 2026 |
About ACLX
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treatin... [Read more]
Financial Performance
In 2025, Arcellx's revenue was $22.29 million, a decrease of -79.35% compared to the previous year's $107.94 million. Losses were -$228.93 million, 113.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for ACLX stock is "Hold." The 12-month stock price target is $115.85, which is an increase of 0.64% from the latest price.
News
Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or brea...
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
As of March 18, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 2 Health Care Stocks That May Crash This Quarter
As of March 4, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Here's Why Shares of Arcellx Are Up Almost 80% Today
Shares of a biotech firm are jumping on a down day for stocks.
Why is Arcellx stock up 80% today? Gilead's $7.8B answer
Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock's move wasn't ...
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences will pay as much as $7.8 billion to acquire its partner Arcellex in its largest deal since 2020, the biopharma company said on Monday, as it looks to strengthen its lineup of cancer tr...
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.
Gilead to acquire Arcellx for $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for ...
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #ACLX--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: AC...
Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurabl...
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...
Cancer Study Buoys These Small Biotechs
Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm's once-daily pill.
Why Is Arcellx Stock Surging Today?
Arcellx Inc. (NASDAQ: ACLX) shared new data on Saturday from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma (RRMM).
Arcellx Transcript: Status Update
Anito-cel shows high efficacy, durable responses, and a favorable safety profile, setting it apart from other CAR T and bispecific therapies. With strong clinical trial results, imminent BLA submission, and robust commercial readiness, it is positioned for broad adoption and potential market expansion.
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...
Arcellx Provides Third Quarter 2025 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...
Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...
Arcellx Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Anito-cel continues to show strong efficacy and a differentiated safety profile in late-line multiple myeloma, with no delayed neurotoxicity observed and high MRD negativity rates. Regulatory and commercial plans remain on track for a 2026 launch, with expansion into earlier lines and additional pipeline progress ongoing.
Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...
Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...
Arcellx Transcript: Status Update
Anito-cel is positioned to lead the myeloma CAR T market with strong efficacy, a highly differentiated safety profile, and rapid, scalable manufacturing through its Kite partnership. Physician and patient research support broad adoption, especially in community and frail patient populations, with commercial launch targeted for mid-to-late 2026.
Arcellx Transcript: TD Cowen's 6th Annual Oncology Innovation Summit
iMMagine-1 trial data for anito-cel show strong efficacy and a differentiated safety profile, with no delayed neurotoxicity observed and manufacturing readiness for launch. Regulatory filings are on track for a mid-to-late 2026 launch, with priority review expected.
Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...